News Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Delayed OTC Markets Other stock markets 07:31:58 01/04/2024 pm IST			5-day change	1st Jan Change
19.48 ^USD	+4.39%		-.--%	-6.75%

07/05	Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	CI
30/04	Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	10/05	AQ
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	07/05	CI
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer	01/05	AQ
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	30/04	CI
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	30/04	CI
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04	AQ
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04	CI
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04	AQ
Hutchmed endometrial cancer treatment application accepted for review	02/04	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04	MT
HSBC in special payout on Canada sale; Astra FDA win	02/04	AN
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	02/04	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02/04	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21/03	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07/03	CI
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	06/03	AQ
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	05/03	MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	05/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Summary

Filters